Discovery of synthetic lethal interactions from large-scale pan-cancer perturbation screens.
Srivatsa S
Nat Commun. 2022 Dec 14;13(1):7748. doi: 10.1038/s41467-022-35378-z
Analysis of off-tumour toxicities of T-cell-engaging bispecific antibodies via donor-matched intestinal organoids and tumouroids.
Harter MF
Nat Biomed Eng. 2023 Dec 19;8(4):345-360. doi: 10.1038/s41551-023-01156-5
Genetic profiling using plasma-derived cell-free DNA in therapy-naïve hepatocellular carcinoma patients: a pilot study.
Ng CKY
Ann Oncol. 29(5):1286-1291. doi: 10.1093/annonc/mdy083
Diagnostic Targeted Sequencing Panel for Hepatocellular Carcinoma Genomic Screening.
Paradiso V
J Mol Diagn. 2018 Aug 22;20(6):836-848. doi: 10.1016/j.jmoldx.2018.07.003
Genomic characterization of metastatic breast cancers.
Bertucci F
Nature. 2019 May 22;569(7757):560-564. doi: 10.1038/s41586-019-1056-z
PipeIT: A Singularity Container for Molecular Diagnostic Somatic Variant Calling on the Ion Torrent Next-Generation Sequencing Platform.
Garofoli A
J Mol Diagn. 2019 Jun 21;21(5):884-894. doi: 10.1016/j.jmoldx.2019.05.001
Systematic identification of novel cancer genes through analysis of deep shRNA perturbation screens.
Montazeri H
Nucleic Acids Res. 49(15):8488-8504. doi: 10.1093/nar/gkab627
Epigenetic priming in chronic liver disease impacts the transcriptional and genetic landscapes of hepatocellular carcinoma.
Gallon J
Mol Oncol. 2021 Dec 29;16(3):665-682. doi: 10.1002/1878-0261.13154
GATA3 and MDM2 are synthetic lethal in estrogen receptor-positive breast cancers.
Bianco G
Commun Biol. 2022 Apr 19;5(1):373. doi: 10.1038/s42003-022-03296-x
Integrative proteogenomic characterization of hepatocellular carcinoma across etiologies and stages.
Ng CKY
Nat Commun. 2022 May 4;13(1):2436. doi: 10.1038/s41467-022-29960-8